The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting.

Russell DrummondSamuel Joseph Paul MalkinMichelle Du PreezXin Ying LeeBarnaby Hunt

Published in: Diabetes, obesity & metabolism (2018)

IDegLira is a cost-effective alternative to BBT with insulin glargine U100 plus insulin aspart, providing equivalent glycaemic control with a simpler treatment regimen for patients with type 2 diabetes inadequately controlled on basal insulin in the UK.

Keyphrases

type diabetes
glycemic control
insulin resistance
stem cells
skeletal muscle
weight loss
adipose tissue
combination therapy